20.5 C
New York
Thursday, June 18, 2026

Tag: regulatory approval

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

JERUSALEM, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended June 30, 2025.

Hyperion Defi to Report Second Quarter 2025 Results on Wednesday, August 13, 2025

Company to host an investor conference call and webcast at 4:30 pm ET
Company to host an investor conference call and webcast at 4:30 pm ET

Longeveron Announces Up To $17.5 Million Public Offering

Longeveron announces the pricing of a public offering of common stock and warrants.

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

– Second Quarter 2025 Financial Results and Corporate Update Rescheduled to Monday, August 11, 2025, at 4:30 p.m. ET –
– Second Quarter 2025 Financial Results and Corporate Update Rescheduled to Monday, August 11, 2025, at 4:30 p.m. ET –

BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update

Call Scheduled for August 14, 2025, at 8:30 AM Eastern Time NEW YORK, Aug. 8, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading...

Bluejay Diagnostics Provides Second Quarter Business and Corporate Update

ACTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing near-patient solutions for critical care, today announced financial results for the quarter ended June 30, 2025, and provided an update on its Symphony IL-6 test program and key operational milestones.

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

– LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 –

SenesTech Reports Second Quarter 2025 Financial Results with Record Revenue and Record Gross Profit Margins

94% Revenue Growth in Evolve™ Rodent Birth Control Products Strong Cash Balance and Sustained Progress Toward Profitability SURPRISE, Ariz., Aug. 7, 2025 /PRNewswire/ -- SenesTech, Inc....

US NCI Sponsors Senhwa Biosciences’ Second Program-IND Submitted for Clinical Trial Targeting MYC-Aberrant Lymphoma

TAIPEI and SAN DIEGO, Aug. 7, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for...

DMG Blockchain Solutions Announces Preliminary July Operational Results, Treasury Update, Launch of Blockseer Explorer

VANCOUVER, British Columbia, Aug. 06, 2025 (GLOBE NEWSWIRE) -- DMG Blockchain Solutions Inc. (TSX-V: DMGI) (OTCQB: DMGGF) (FRANKFURT: 6AX) ("DMG" or the "Company"), a vertically integrated blockchain and data center technology company, today announces its preliminary operational results for July 2025:

Energy Fuels Announces Q2-2025 Results

Record-breaking performance at U.S. uranium mine to drive lower-cost U3O8 production; advancement of world class rare earth element and heavy mineral sands projects, including...

Energy Fuels Announces Q2-2025 Results

Record-breaking performance at U.S. uranium mine to drive lower-cost U3O8 production; advancement of world class rare earth element and heavy mineral sands projects, including...

Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight

The dynamics of the urothelial carcinoma market are anticipated to change due to the demand for innovative therapies, particularly in chemotherapy and immunotherapy, and...

Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight

The dynamics of the urothelial carcinoma market are anticipated to change due to the demand for innovative therapies, particularly in chemotherapy and immunotherapy, and...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsRegulatory approval